Omics Technology facility

组学技术设施

基本信息

批准号：
10703083
负责人：
Liang Cao
金额：
$ 82.28万
依托单位：
DIVISION OF BASIC SCIENCES - NCI
依托单位国家：
美国
项目类别：
财政年份：
资助国家：
美国
起止时间：
至
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10703083
关键词：
ATAC-seq Algorithms Antibodies Area Bioinformatics Biological Biological Assay Biology CCR Cells ChIP-seq Classification Clinical Communities Computational Biology Contractor Cooperative Research and Development Agreement Custom DNA DNA analysis DNA sequencing Data Data Analyses Detection Development Enhancers Epigenetic Process Foundations Funding Gene Rearrangement Genes Genetic Genome Goals Immunogenomics Industrialization Intention Internet Laboratories Left Machine Learning Malignant Neoplasms Mediating Methods Micrococcal Nuclease Molecular Profiling Molecular Target Mutation Detection Oncogenes Positioning Attribute Proteomics Protocols documentation RNA Research Research Personnel Resources Sequence Analysis Structure T-Lymphocyte Technology Training Tumor Antigens United States National Institutes of Health Validation Work assay development base biomarker development clinical biomarkers convolutional neural network epigenetic regulation exome sequencing genome sequencing innovation mass spectrometric imaging member new technology next generation sequencing operation recruit response screening single-cell RNA sequencing targeted sequencing technology development tool transcriptome sequencing tumor whole genome

项目摘要

As the project was started in this fiscal year, the main effort was focused on the establishment of operation and in the development of core technologies. A. Team formation: 1. Web lab: Two additional members were transferred to us in April of FY22 from the previous Molecular Profile/Clinomics Core, one of which had since left NCI in June 22. We'll fill in this vacate position in FY23. 2. IT team: Two members were recruited to the IT team via the NCI Frederick contractor. This IT team is currently helping to establish the pipelines for Next Generation Sequencing (NGS) data analysis. B. Core technology development. We are mainly focused on establishing NGS-based technologies for discovery cancer drivers, and for understanding biological mechanisms. Specifically, the following technologies are established or near establishment. 1. NGS for cancer mutation detection. We adapted methods for both DNA and RNA Exome sequencing aimed for detection SNV, deletion, an insertion. 2. NGS for expression and fusion detection. The staff in the lab were trained for RNA Exome seq for the detection of fusions, and for expression analysis. 3. Epigenetic regulation. We adapted two different methods for chip-seq, including antibody-mediated DNA cutting by micrococcal nucleases and transposes. 4. Targeted sequencing of cancer gene panels 5. Customized assay development and sequencing of genes involved in T-cell mediated responses against tumor antigens 6. Validation of the NGS methods for their intended research or clinical use, respectively 7. Refining the analytical pipelines for NGS data analysis

随着该项目在本财政年度开始，主要努力集中在建立运营和核心技术的发展上。 A.团队组合：1。WebLab：另外两个成员于4月从以前的Molecular Profile/Clinomics Core转移给了我们，其中一个从6月22日离开NCI。我们将填补23财年的撤离职位。 2。IT团队：通过NCI Frederick承包商将两名成员招募到IT团队。该IT团队目前正在帮助建立下一代测序（NGS）数据分析的管道。 B.核心技术开发。我们主要专注于建立基于NGS的发现癌症驱动因素以及理解生物学机制的技术。具体而言，以下技术是建立或附近建立的。 1。NGS用于癌症突变检测。我们为DNA和RNA外显子组测序进行了调整，旨在检测SNV，缺失，插入。 2。NGS用于表达和融合检测。实验室的工作人员接受了RNA外显子SEQ的培训，以检测融合和表达分析。 3。表观遗传调节。我们为CHIP-SEQ提供了两种不同的方法，包括通过微球菌核酸酶和转置切割抗体介导的DNA切割。 4。针对癌症基因面板的靶向测序。定制的测定开发和对肿瘤抗原的T细胞介导反应的基因的测序6. NGS方法的验证分别用于其预期的研究或临床用途7。精炼NGS数据分析分析管道